Loading...
Market
How will Novo Nordisk stock respond to Ozempic's Alzheimer's risk reduction finding by end of 2024?
2
Resolution / Starting Odds
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Stock market data and financial news reports
Story
Study Finds Ozempic Cuts Alzheimer's Risk by 70% in Type 2 Diabetes
Oct 24, 2024, 11:11 AM
An observational study analyzing medical records has found that semaglutide, the active ingredient in diabetes medications like Ozempic and Wegovy developed by Novo Nordisk, may significantly reduce the risk of Alzheimer's disease in people with type 2 diabetes. The study, published Thursday, showed that patients taking Ozempic had a 70% lower risk of being diagnosed with Alzheimer's compared to those taking other diabetes drugs. This finding suggests potential benefits of semaglutide in neurodegenerative diseases beyond its established use in managing diabetes and aiding weight loss.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Significant increase • 25%
Moderate increase • 25%
No significant change • 25%
Decrease • 25%